AML with RUNX1T1::RUNX1 fusion is known to be associated with a complete remission rate and a high cure rate after high-dose cytarabine consolidation therapy; thus, allogeneic hematopoietic stem cell transplantation in first remission is not recommended for these patients. This evidence concerns the gene RUNX1 and acute myeloid leukemia.